-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.↓
Börse NasdaqUSDISIN US14817C1071-
CASSAVA SCIENCES INCBörse Gettex System der Börse MünchenEURSymbol PX91
-
CASSAVA SCIENCES INCBörse Börse DüsseldorfEURSymbol PX91
-
CASSAVA SCIENCES INCBörse Börse StuttgartEURSymbol PX91
-
CASSAVA SCIENCES INCBörse Tradegate System der Deutsche Börse AG (60%)EURSymbol PX91
-
CASSAVA SCIENCES INCBörse Quotrix System der Börse DüsseldorfEURSymbol PX91
-
Cassava SciencesBörse NasdaqISIN US14817C1071 WKN: A2PGL8USDSymbol SAVA
-
ISIN US14817C1071 WKN: A2PGL8USDSymbol SAVA
-
EURSymbol PX91
-
EURSymbol PX91
-
EURSymbol PX91
-
MXN
-
ISIN US14817C1071
WKN A2PGL8
Symbol SAVA
Währung
USD
Börse
Nasdaq Zeitzone: Europe/Berlin
Firmenname
Cassava Sciences, Inc
Marktkapitalisierung
2.615.467.488 (+- 23%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
2.011.934.976 oder 3.219.000.000
Mitarbeiter
18 (+- 49%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
9 oder 26 Mitarbeiter
EBITDA -4.572.000
PEGRatio None
Buchwert 0.937
Zahlte zuletzt am 13.12.2012 eine Dividende von 5,25 . Seit damals wurde keine Dividende mehr ausgeschüttet Übersicht
Die letzten Quartalsergebnisse Erwarteter Gewinn je Aktie beim aktuellen Wert von 64,96 EUR -13,73%
Portrait der Cassava Sciences Aktie
Das Unternehmen Cassava Sciences, Inc aus USA beschäftigt 18 Mitarbeiter und ist in den Bereichen Chemie & Pharma, Biotechnologie tätig.
Das Unternehmen Cassava Sciences, Inc ist nur in einem ETFs enthalten und somit ein unbekanntes oder von Investoren gemiedenes Unternehmen. Der ETF iShares MSCI USA Small Cap UCITS ETF gewichtet Cassava Sciences mit 0,08%.
Ein ETF investiert in Cassava Sciences, Inc
Dir gefallen die Informationen zu Cassava Sciences?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
Dir gefallen die Informationen zu Cassava Sciences?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
Dir gefallen die Informationen zu Cassava Sciences?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
Dir gefallen die Informationen zu Cassava Sciences?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
107 News & Informationen zur Cassava Sciences Aktie
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Cassava Sciences, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cassava Sciences, Inc. for violations of the securities… | August 26, 2021
Cassava Sciences Likely To Survive Attack On Alzheimer's Drug (NASDAQ:SAVA)
A citizen's petition filed with the FDA insisted that data from earlier studies of Cassava Sciences' Alzheimer's Drug had been manipulated. Read more here.
(SAVA) Cassava Alert: Did You Lose Money on Your Investment? Contact Johnson Fistel Regarding Investigation
SAN DIEGO, Aug. 25, 2021 (GLOBE NEWSWIRE) — Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of the federal…
Glancy Prongay & Murray LLP, A National Class Action Law Firm, Continues Investigation Of Cassava Sciences, Inc. (SAVA) On Behalf Of Investors
Glancy Prongay & Murray LLP (“GPM”), a national investor rights law firm, continues its investigation on behalf of Cassava Sciences, Inc. (“Cassava” or the
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.11% By Investing.com
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.11%
S&P 500, Nasdaq close at new highs as investors look to upcoming speech from Fed Chair Powell
Deutsche Bank said retail investors have been key players in the stock market rally Johannes Eisele/Getty Images US stocks closed at record hi…
Mid-Afternoon Market Update: Dow Rises 100 Points; ScanSource Shares Surge Following Q4 Results
Toward the end of trading Wednesday, the Dow traded up 0.30% to 35,470.78 while the NASDAQ rose 0.12% to 15,038.45. The S&P also rose, gaining…
Mid-Morning Market Update: Markets Edge Higher; Dick's Sporting Goods Beats Q2 Views
Following the market opening Wednesday, the Dow traded up 0.07% to 35,389.32 while the NASDAQ rose 0.17% to 15,045.45. The S&P also rose, gaining 0.14% …
Wall Street Opens Mixed as Calm Descends Ahead of Fed; Dow Down 50 Pts By Investing.com
Wall Street Opens Mixed as Calm Descends Ahead of Fed; Dow Down 50 Pts
Cassava Sciences Stock Plummets on Request to Halt Drug Trials
Cassava Sciences says challenges to its Alzheimer's drug are 'false and misleading.'
Futures Flat Near All Time High As Traders Brace For J-Hole
ZeroHedge – On a long enough timeline, the survival rate for everyone drops to zero
Cassava Sciences falls on concerns over Alzheimer’s trial (NASDAQ:SAVA)
With a decline of ~23.5%, Cassava Sciences (SAVA) has extended losses into the pre-market in reaction to an after-market report that raised concerns over the quality of the studies into…
Cassava Sciences Responds to Allegations
AUSTIN, Texas, Aug. 25, 2021 — Cassava Sciences, Inc. , a biotechnology company focused on Alzheimer’s disease, today issued a response to claims that were posted on-line yesterday… | August 25, 2021
Cassava Sciences Responds To Allegations
AUSTIN, Texas, Aug. 25, 2021 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer's disease, today issued a
5 Penny Stocks That Turned $2,500 Into Over $29,000 In 2021 So Far
Hot Penny Stocks That Scored Huge For Traders In 2021
5 Penny Stocks That Turned $2,500 Into Over $29,000 In 2021 So Far
Bleichroeder LP Buys Pioneer Merger Corp, CM Life Sciences III Inc, Isleworth Healthcare Acquisition Corp, Sells SPDR Gold Shares ETF, Durect Corp, Brunswick Corp
GuruFocus Article or News written by insider and the topic is about:
15 Best Penny Stocks to Buy Now
Retail investors who do not have the billions of dollars that institutional investors have access to often look towards penny stocks as an entry into the world of investing.
Mid-Afternoon Market Update: Dow Drops 50 Points; IEC Electronics Shares Spike Higher
Toward the end of trading Thursday, the Dow traded down 0.14% to 35,435.25 while the NASDAQ rose 0.29% to 14,808.42. The S&P also rose, gainin…
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Cassava Sciences, Inc. – SAVA
NEW YORK, Aug. 11, 2021 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. (“Cassava” or the “Company”)
Are Penny Stocks Worth It? 5 That Deserve Your Attention Now
3 Things About Cassava Sciences That Smart Investors Know
Things are changing, but the picture is getting more positive as time goes on.
Hot Biotech Stocks To Watch After Sanofi’s Acquisition Of Translate Bio
Alzheimer’s biotech Cassava Sciences stock jumps 10% post Q2 results (NASDAQ:SAVA)
Alzheimer’s disease biotech Cassava Sciences (SAVA) soars 10.4% premarket after announcing financial results for Q2 ended June 30, 2021. R&D expenses were $3.9M compared to $0.6M for…
Cassava Sciences Reports Second Quarter 2021 Financial Results
– Conference Call Today at 9 a.m. ET -…
Cassava Sciences Inc. Stock Quote (U.S.: Nasdaq)
SAVA | Complete Cassava Sciences Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
5 Ultra-Popular Stocks to Avoid Like the Plague in August
These stocks look to be more trouble than they're worth.
Cassava Sciences Announces Conference Call for Second Quarter Financial Results
– Call-in on Tuesday, August 3rd at 9 a.m. ET -…
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.42% By Investing.com
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.42%
Cassava Sciences' Simufilam First Alzheimer's Drug To Work At 9 Months (NASDAQ:SAVA)
Cassava Sciences' Simufilam is the first AD drug to show a cognitive improvement at 9 months, with a gaudy 18% mean improvement from baseline.
This Biotech Stock was Once a Penny Stock but is Now Making Big Moves on the Nasdaq!
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.44% By Investing.com
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.44%
Here's Why Annovis Bio, Anavex Life Sciences, and Cassava Sciences Sank on Thursday
A clinical-trial flop for Annovis Bio is reminding investors that developing new drugs for Alzheimer's disease is an extremely risky business.
Mid-Morning Market Update: Markets Open Higher; Mastercard Profit Beats Estimates
Following the market opening Thursday, the Dow traded up 0.44% to 35,085.92 while the NASDAQ rose 0.27% to 14,802.51. The S&P also rose, gaining 0.45% …
Stocks That Hit 52-Week Highs On Thursday
Thursday's morning session saw 167 companies set new 52-week highs.
Points of Interest: ASML Holding (NASDAQ:ASML) was the largest company by …
Should You Invest in This Seemingly Unstoppable Alzheimer's Biotech?
This popular life science company has a fair but risky shot of developing a novel drug to treat Alzheimer's disease.
Cassava Sciences: Alzheimer's Data May Offer Upside Potential (NASDAQ:SAVA)
Cassava Sciences is developing an Alzheimer's therapy in Simufilam. Check out Cassava's progress on this and see how SAVA stock will be reacting to Thursday's data.
5 Reasons Cassava Sciences Could Still Be The Most Undervalued Stock (NASDAQ:SAVA)
Cassava Sciences is possibly on the verge of validating simufilam as a miracle drug in Alzheimer's disease. If that happens, then we think there is a great deal of upside left in the stock.
Cassava Sciences Announces Positive Data with SavaDx from a Randomized Controlled Phase 2b Study of Simufilam
SavaDx Detected Significant Changes in Plasma Levels of Altered Filamin A in Patients with Alzheimer’s Disease Before and After Simufilam…
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was s…